CD133 mRNA may be a suitable prognostic marker for human breast cancer

Pu, Xia

doi:10.21037/sci.2017.10.03

Cited by 23 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of CD44 and CD133 in colorectal cancers can predict metastasis ( 470 ), however, no correlation to patient outcome could be detected ( 471 ). In breast cancers, CD133 mRNA was suggested to be suitable for prognosis prediction ( 193 , 472 ) and CD133 protein has been correlated to a poor prognosis ( 193 ). Pre-clinical therapeutic approaches cover antibody-based targeting of colorectal ( 341 , 342 ) as well as breast cancers ( 188 ) (compare Tables 1 – 5 ).…”

Section: Cscs and Their Origin At Tumor Initiationmentioning

confidence: 99%

Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies

et al. 2020

View full text Add to dashboard Cite

The use of biomarkers in diagnosis, therapy and prognosis has gained increasing interest over the last decades. In particular, the analysis of biomarkers in cancer patients within the pre- and post-therapeutic period is required to identify several types of cells, which carry a risk for a disease progression and subsequent post-therapeutic relapse. Cancer stem cells (CSCs) are a subpopulation of tumor cells that can drive tumor initiation and can cause relapses. At the time point of tumor initiation, CSCs originate from either differentiated cells or adult tissue resident stem cells. Due to their importance, several biomarkers that characterize CSCs have been identified and correlated to diagnosis, therapy and prognosis. However, CSCs have been shown to display a high plasticity, which changes their phenotypic and functional appearance. Such changes are induced by chemo- and radiotherapeutics as well as senescent tumor cells, which cause alterations in the tumor microenvironment. Induction of senescence causes tumor shrinkage by modulating an anti-tumorigenic environment in which tumor cells undergo growth arrest and immune cells are attracted. Besides these positive effects after therapy, senescence can also have negative effects displayed post-therapeutically. These unfavorable effects can directly promote cancer stemness by increasing CSC plasticity phenotypes, by activating stemness pathways in non-CSCs, as well as by promoting senescence escape and subsequent activation of stemness pathways. At the end, all these effects can lead to tumor relapse and metastasis. This review provides an overview of the most frequently used CSC markers and their implementation as biomarkers by focussing on deadliest solid (lung, stomach, liver, breast and colorectal cancers) and hematological (acute myeloid leukemia, chronic myeloid leukemia) cancers. Furthermore, it gives examples on how the CSC markers might be influenced by therapeutics, such as chemo- and radiotherapy, and the tumor microenvironment. It points out, that it is crucial to identify and monitor residual CSCs, senescent tumor cells, and the pro-tumorigenic senescence-associated secretory phenotype in a therapy follow-up using specific biomarkers. As a future perspective, a targeted immune-mediated strategy using chimeric antigen receptor based approaches for the removal of remaining chemotherapy-resistant cells as well as CSCs in a personalized therapeutic approach are discussed.

show abstract

Section: Cscs and Their Origin At Tumor Initiationmentioning

confidence: 99%

Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Several lines of evidence have suggested CD133 as a prognostic marker in many types of cancers including breast cancer, lung cancer, gastric cancer, colorectal cancer and so on (Alamgeer et al, 2013, Horst et al, 2009b, Ishigami et al, 2010, Wu et al, 2014, Xia, 2017). In addition to cancer initiation, development, and metastasis, CD133 also enhances therapeutic resistance including chemo drugs and radiation.…”

Section: Potential Of Targeting Cd133 In Cancer Therapymentioning

confidence: 99%

CD133 as a regulator of cancer metastasis through the cancer stem cells

Liou

2019

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

Cancer stem cells are the cancer cells that have abilities to self-renew, differentiate into defined progenies, and initiate and maintain tumor growth. They also contribute to cancer metastasis and therapeutic resistance, both of which are the major causes of cancer mortality. Among the reported makers of the cancer stem cells, CD133 is the most well-known marker for isolating and studying cancer stem cells in different types of cancer. The CD133high population of cancer cells are not only capable of self-renewal, proliferation, but also highly metastatic and resistant to therapy. Despite very limited information on physiological functions of CD133, many ongoing studies are aimed to reveal the mechanisms that CD133 utilizes to modulate cancer dissemination and drug resistance with a long-term goal for bringing down the number of cancer deaths. In this review, in addition to the regulation of CD133, and its involvement in cancer initiation, and development, the recent updates on how CD133 modulates cancer dissemination, and therapeutic resistance are provided. The key signaling pathways that are upstream or downstream of CD133 during these processes are summarized. A comprehensive understanding of CD133-mediated cancer initiation, development, and dissemination through its pivotal role in cancer stem cells will offer new strategies in cancer therapy.

show abstract

“…O’Brien et al and Ricci et al identified that CD133 + colon cancer cells had the ability to initiate tumor growth. In BC, although there are studies that identify the CD133 as a good BCSC marker [ 43 , 44 ], its prognostic role has not been well defined yet. The CD49f also known as integrin α6 (ITGA6) has been related to cell adhesion and signaling.…”

Section: Breast Cancer Stem Cells (Bcscs)mentioning

confidence: 99%

Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance

2018

View full text Add to dashboard Cite

Despite advances in breast cancer diagnosis and treatment, many patients still fail therapy, resulting in disease progression, recurrence, and reduced overall survival. Historically, much focus has been put on the intrinsic subtyping based in the presence (or absence) of classical immunohistochemistry (IHC) markers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-related protein (HER2). However, it is widely understood that tumors are composed of heterogeneous populations of cells with a hierarchical organization driven by cancer stem cells (CSCs). In breast tumors, this small population of cells displaying stem cell properties is known as breast CSCs (BCSCs). This rare population exhibit a CD44+/CD24−/low phenotype with high ALDH activity (ALDH+), and possesses higher tolerability to chemotherapy, hormone therapy, and radiotherapy and is able to reproduce the bulk of the tumor after reduction of cell populations sensitive to first-line therapy leading to disease relapse. In this review, we present special attention to BCSCs with future directions in the establishment of a therapy targeting this population. Drugs targeting the main BCSCs signaling pathways undergoing clinical trials are also summarized.

show abstract

CD133 mRNA may be a suitable prognostic marker for human breast cancer

Cited by 23 publications

References 15 publications

Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies

Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies

CD133 as a regulator of cancer metastasis through the cancer stem cells

Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance

Contact Info

Product

Resources

About